MFN is reshaping global pharma pricing. The real challenge is not price reduction, but controlling how value propagates across markets. This paper explains how leading organizations are redesigning their commercial systems to protect global asset value.

Chemical companies are losing control over pricing and margins. Discover how Commercial Transformation restores visibility, governance, and execution discipline.

From strategy to execution, leading organizations are transforming pricing into a governed commercial system that delivers sustainable performance.

Pharma is not facing a pricing problem, but a fragmented commercial system. Discover why CEOs must now lead Commercial Transformation as an integrated operating model.

Gross-to-Net is no longer a reporting exercise. Discover how leading organizations turn pricing complexity into sustainable revenue through structured governance and AI-powered commercial systems.

IT companies lose up to 12% of EBIT due to fragmented commercial decisions. Learn how structured Commercial Transformation restores control, transparency and profitability.

At EPA 2026, Stratence Partners will lead two executive sessions in the Pricing and AI tracks and host business-focused Poster Sessions on Commercial Transformation, AI Powered. Meet us at Booth 300A.

Ahead of EPA 2026, Stratence Partners is hosting a closed-door VIP Dinner for selected VP and C-level executives in Pricing, Market Access, Commercial and Finance governance.

Animal Health companies face structural margin erosion from fragmented pricing, opaque gross-to-net dynamics, and misaligned execution. AI-Powered Commercial Transformation is no longer optional — it is strategic.

EPA 2026: From Attendance to Impact The World Evidence, Pricing & Access Congress remains Europe’s most relevant gathering for senior leaders in pricing, market access, HEOR, and commercial strategy. But attendance alone does not create value. Impact comes from addressing structural weaknesses that silently erode EBIT year after year. As a global firm specialized in Commercial Transformation, AI Powered, Stratence Partners returns to EPA 2026 with two focused executive sessio

In Medical Devices, margin erosion rarely comes from innovation. It comes from fragmented commercial governance. Stratence Partners explains how Commercial Transformation, AI Powered, restores structural control and delivers measurable EBIT impact within year one.

SPIE in Oil & Gas restores pricing discipline, deal transparency and commercial execution control in volatile energy markets.

In Oil & Gas, margin erosion is rarely caused by strategy. It is caused by weak execution, fragmented pricing governance and disconnected commercial decisions.

At EPA 2026, Stratence Partners will lead two executive sessions on Gross-to-Net discipline and AI-driven commercial transformation — focused on execution, governance and measurable impact.

SPIE in Chemicals provides a unified commercial ecosystem to regain control over pricing, execution and margin discipline in volatile markets.

Stratence Partners shines at the World Evidence, Pricing & Access Congress 2025, sharing strategic insights on digital transformation and pricing excellence to drive financial sustainability and patient access.

🚀 Fernando Ventureira leads the Pricing Track at EPA Congress 2025 today! Stop by Booth 50 to meet the team & discuss pricing strategy!

On March 6th, Stratence Partners will lead key discussions in the Pricing Track at the EPA Congress. Don’t miss our sesión on healthcare

On March 6th, Stratence Partners will lead key discussions in the Pricing Track at the EPA Congress. Don’t miss our sesión on healthcare

Stratence Partners elevated our Data Science capabilities, optimizing product strategies and significantly boosting company profitability.